Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Chile | Colombia | Cyprus | Czech | Dominican Republic | Egypt | Estonia | Finland | Greece | Hong Kong | Hungary | India | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: LEO Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Dermatitis, Atopic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
19-02/MPA-S | P1 |
Unknown Status |
Dermatitis, Atopic |
2025-12-31 |
|
22-01/MPA-C | P3 |
Unknown Status |
Dermatitis, Atopic |
2025-04-26 |
|
2019-002686-35 | P3 |
Active, not recruiting |
Dermatitis, Atopic |
2023-06-07 |